{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T19:17:49Z","timestamp":1648667869924},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s40263-019-00654-y","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T11:15:29Z","timestamp":1567250129000},"page":"933-942","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Subjective Versus Objective Outcomes of Antipsychotics for the Treatment of Neuropsychiatric Symptoms Associated with Dementia"],"prefix":"10.1007","volume":"33","author":[{"given":"Eline J.","family":"Vredeveld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa A.","family":"Hulshof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sytse U.","family":"Zuidema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrika J.","family":"Luijendijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,31]]},"reference":[{"key":"654_CR1","first-page":"1001","volume":"2012","author":"R Butler","year":"2012","unstructured":"Butler R, Radhakrishnan R. Dementia. BMJ Clin Evid. 2012;2012:1001.","journal-title":"BMJ Clin Evid"},{"issue":"3","key":"654_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/archpsyc.1997.01830150083012","volume":"54","author":"DP Devanand","year":"1997","unstructured":"Devanand DP. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997;54(3):257.","journal-title":"Arch Gen Psychiatry."},{"issue":"3","key":"654_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1176\/jnp.15.3.340","volume":"15","author":"M Steinberg","year":"2003","unstructured":"Steinberg M, Sheppard J-M, Tschanz JT, Norton MC, Steffens DC, Breitner JCS, et al. The incidence of mental and behavioral disturbances in dementia: the cache county study. J Neuropsychiatry Clin Neurosci. 2003;15(3):340\u20135.","journal-title":"J Neuropsychiatry Clin Neurosci."},{"issue":"Suppl 21","key":"654_CR4","first-page":"3","volume":"62","author":"SI Finkel","year":"2001","unstructured":"Finkel SI. Behavioral and Psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers. J Clin Psychiatry. 2001;62(Suppl 21):3\u20136.","journal-title":"J Clin Psychiatry."},{"issue":"1","key":"654_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/0891988706292762","volume":"20","author":"S Zuidema","year":"2007","unstructured":"Zuidema S, Koopmans R, Verhey F. Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients. Int J Geriatr Psychiatry Neurol. 2007;20(1):41\u20139.","journal-title":"Int J Geriatr Psychiatry Neurol."},{"key":"654_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000093102","volume":"22","author":"M de Vugt","year":"2006","unstructured":"de Vugt M, Riedijk S, Aalten P, Tibben A, van Swieten J, Verhey F. Impact of behavioural problems on spousal caregivers: a comparison between Alzheimer\u2019s disease and frontotemporal dementia. Dement Geriatr Cogn Disord. 2006;22:35\u201341.","journal-title":"Dement Geriatr Cogn Disord."},{"issue":"3","key":"654_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/(SICI)1099-1166(199703)12:3<331::AID-GPS495>3.0.CO;2-J","volume":"12","author":"RF Coen","year":"1997","unstructured":"Coen RF, Swanwick GRJ, O\u2019Boyle CA, Coakley D. Behaviour disturbance and other predictors of carer burden in Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 1997;12(3):331\u20136.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"11","key":"654_CR8","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1017\/S1041610216001150","volume":"28","author":"SIM Janus","year":"2016","unstructured":"Janus SIM, van Manen JG, IJzerman MJ, Zuidema SU. Psychotropic drug prescriptions in Western European nursing homes. Int Psychogeriatr. 2016;28(11):1775\u201390.","journal-title":"Int Psychogeriatr."},{"issue":"3","key":"654_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1017\/S1041610209008916","volume":"21","author":"RM Nijk","year":"2009","unstructured":"Nijk RM, Zuidema SU, Koopmans RTCM. Prevalence and correlates of psychotropic drug use in Dutch nursing-home patients with dementia. Int Psychogeriatr. 2009;21(3):485\u201393.","journal-title":"Int Psychogeriatr."},{"issue":"3","key":"654_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000346144","volume":"82","author":"C Baethge","year":"2013","unstructured":"Baethge C, Assall OP, Baldessarini RJ. Systematic review of blinding assessment in randomized controlled trials in schizophrenia and affective disorders 2000\u20132010. Psychother Psychosom. 2013;82(3):152\u201360.","journal-title":"Psychother Psychosom."},{"issue":"7644","key":"654_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","volume":"336","author":"L Wood","year":"2008","unstructured":"Wood L, Egger M, Gluud LL, Schulz KF, J\u00fcni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336(7644):601\u20135.","journal-title":"BMJ."},{"issue":"3","key":"654_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.7326\/0003-4819-136-3-200202050-00022","volume":"136","author":"KF Schulz","year":"2002","unstructured":"Schulz KF. The landscape and lexicon of blinding in randomized trials. Ann Intern Med. 2002;136(3):254.","journal-title":"Ann Intern Med."},{"key":"654_CR13","first-page":"CD003012","volume":"1","author":"J Moncrieff","year":"2004","unstructured":"Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev. 2004;1:CD003012.","journal-title":"Cochrane Database Syst Rev."},{"issue":"8","key":"654_CR14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/archpsyc.1997.01830200078011","volume":"54","author":"M Ba\u015fo\u011flu","year":"1997","unstructured":"Ba\u015fo\u011flu M, Marks I, Livanou M, Swinson R. Double-blindness procedures, rater blindness, and ratings of outcome. Observations from a controlled trial. Arch Gen Psychiatry. 1997;54(8):744\u20138.","journal-title":"Arch Gen Psychiatry."},{"issue":"3","key":"654_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00213-009-1743-9","volume":"208","author":"B Colagiuri","year":"2010","unstructured":"Colagiuri B, Boakes RA. Perceived treatment, feedback, and placebo effects in double-blind RCTs: an experimental analysis. Psychopharmacology (Berl). 2010;208(3):433\u201341.","journal-title":"Psychopharmacology (Berl)."},{"issue":"3","key":"654_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1503\/cmaj.070693","volume":"178","author":"C Barbui","year":"2008","unstructured":"Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ. 2008;178(3):296\u2013305.","journal-title":"CMAJ."},{"key":"654_CR17","volume-title":"WHO collaborating centre for drugs statistics methodology","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. WHO collaborating centre for drugs statistics methodology. Geneva: World Health Organization; 2013."},{"key":"654_CR18","unstructured":"US Food and Drug Administration; 2016. \n                    https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm\n                    \n                  . Accessed 24 June 2019."},{"key":"654_CR19","unstructured":"Wikipedia. Typical antipsychotics. Wikipedia, free encyclopedia; 2015. \n                    https:\/\/en.wikipedia.org\/wiki\/Typical_antipsychotics\n                    \n                  ."},{"key":"654_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic reviews of interventions. Version 5.0.1","author":"J Higgins","year":"2008","unstructured":"Higgins J, Altman D. Assessing risk of bias in included studies. In: Cochrane H, Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.0.1. London: The Cochrane Collaboration; 2008."},{"issue":"15","key":"654_CR21","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa061240","volume":"355","author":"L Schneider","year":"2006","unstructured":"Schneider L, Tariot P, Dagerman K, Davis S, Hsiao J, Ismail S, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease. N Engl J Med. 2006;355(15):1525\u201338.","journal-title":"N Engl J Med."},{"issue":"2","key":"654_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1017\/S1041610206003942","volume":"19","author":"J Rabinowitz","year":"2007","unstructured":"Rabinowitz J, Katz I, De Deyn P, Greenspan A, Brodaty H. Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer\u2019s disease using risperidone. Int Psychogeriatr. 2007;19(2):227\u201340.","journal-title":"Int Psychogeriatr."},{"key":"654_CR23","first-page":"411","volume":"76","author":"L Cahn","year":"1973","unstructured":"Cahn L, Diesfeldt H. The use of neuroleptics in the treatment of dementia in old age. Psychiatr Neurol Neurochir. 1973;76:411\u201320.","journal-title":"Psychiatr Neurol Neurochir."},{"issue":"491","key":"654_CR24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1192\/bjp.112.491.989","volume":"112","author":"R Barton","year":"1966","unstructured":"Barton R, Hurst L. Unnecessary use of tranquilizers in elderly patients. Br J Psychiatry. 1966;112(491):989\u201390.","journal-title":"Br J Psychiatry."},{"issue":"8","key":"654_CR25","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1001\/archneur.1989.00520440036018","volume":"46","author":"D Devanand","year":"1989","unstructured":"Devanand D, Sackeim H, Brown R, Mayeux R. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer\u2019s disease. Arch Neurol. 1989;46(8):854\u20137.","journal-title":"Arch Neurol."},{"key":"654_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000245301","volume":"12","author":"G Tewfik","year":"1970","unstructured":"Tewfik G, Jain V, Harcup M, Magowan S. Effectiveness of various tranquillisers. Geront Clink. 1970;12:351\u20139.","journal-title":"Geront Clink."},{"issue":"2","key":"654_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/0891988704264535","volume":"17","author":"K Meguro","year":"2004","unstructured":"Meguro K, Meguro M, Tanaka Y, Akanuma K, Yamaguchi K, Itoh M. Risperidone is effective for wandering and disturbed sleep\/wake patterns in Alzheimer\u2019s disease. J Geriatr Psychiatry Neurol. 2004;17(2):61\u20137.","journal-title":"J Geriatr Psychiatry Neurol."},{"issue":"1","key":"654_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jamda.2008.06.006","volume":"10","author":"S Rappaport","year":"2009","unstructured":"Rappaport S, Marcus R, Manos G, McQuade R, Oren D. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer\u2019s, vascular, or mixed dementia. J Am Med Dir Assoc. 2009;10(1):21\u20137.","journal-title":"J Am Med Dir Assoc."},{"issue":"4","key":"654_CR29","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S0893-133X(01)00365-7","volume":"26","author":"K Meehan","year":"2002","unstructured":"Meehan K, Wang H, David S, Nisivoccia J, Jones B, Beasley C, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26(4):494\u2013504.","journal-title":"Neuropsychopharmacology."},{"issue":"4","key":"654_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/070674377201700408","volume":"17","author":"H Lehmann","year":"1972","unstructured":"Lehmann H, Ban T, Saxena M. Nicotinic acid, thioridazine, fluoxymesterone and their combinations in hospitalized geriatric patients. Can Psychiatr Assoc J. 1972;17(4):315\u201320.","journal-title":"Can Psychiatr Assoc J."},{"key":"654_CR31","first-page":"596","volume":"17","author":"LD Hamilton","year":"1962","unstructured":"Hamilton LD, Bennett JL. Acetophenazine for hyperactive geriatric patients. Geriatrics. 1962;17:596\u2013601.","journal-title":"Geriatrics."},{"issue":"17","key":"654_CR32","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","volume":"68","author":"R Kurlan","year":"2007","unstructured":"Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356\u201363.","journal-title":"Neurology."},{"issue":"11","key":"654_CR33","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/gps.1397","volume":"20","author":"J Kennedy","year":"2005","unstructured":"Kennedy J, Deberdt W, Siegal A, Micca J, Degenhardt E, Ahl J, et al. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer\u2019s dementia. Int J Geriatr Psychiatry. 2005;20(11):1020\u20137.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"10","key":"654_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1600-0447.1986.tb10541.x","volume":"73","author":"SA Ather","year":"1986","unstructured":"Ather SA, Shaw SH, Stoker MJ. A comparison of chlormethiazole and thioridazine in agitated confusional states of the elderly. Acta Psychiatr Scand. 1986;73(10):81\u201391.","journal-title":"Acta Psychiatr Scand."},{"key":"654_CR35","unstructured":"Bamrah S. A multicentre, double-blind, randomised, parallel group comparison of seroquel and haloperidol in the treatment of elderly patients presenting with dementia and psychosis. National Research Register; 1999."},{"issue":"8","key":"654_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1532-5415.1972.tb01644.x","volume":"20","author":"D Birkett","year":"1972","unstructured":"Birkett D, Boltuch B. Chlorpromazine in geriatric psychiatry. J Am Geriatr Soc. 1972;20(8):403\u20136.","journal-title":"J Am Geriatr Soc."},{"issue":"2\u20133","key":"654_CR37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000082353","volume":"19","author":"K Martin-Cook","year":"2005","unstructured":"Martin-Cook K, Hynan L, Rice-Koch K, Svetlik D, Weiner M. Responsiveness of the quality of life in late-stage dementia scale to psychotropic drug treatment in late-stage dementia. Dement Geriatr Cogn Disord. 2005;19(2\u20133):82\u20135.","journal-title":"Dement Geriatr Cogn Disord."},{"issue":"3","key":"654_CR38","first-page":"234","volume":"21","author":"E Engstrand","year":"1967","unstructured":"Engstrand E. Buronil og promazinbehandling av senildemente: En dobbeltblind unders\u00f8kelse. Nord J Psychiatry. 1967;21(3):234\u201340.","journal-title":"Nord J Psychiatry."},{"key":"654_CR39","first-page":"873","volume":"12","author":"C Spagnolo","year":"1983","unstructured":"Spagnolo C, Dall\u2019asta D, Iannuccelli M, Cucinotta D, Passeri M. A controlled double-blind trial comparing etoperidone with thioridazine in the management of severe senile dementia. Drugs Exp Clin Res. 1983;12:873\u201380.","journal-title":"Drugs Exp Clin Res."},{"issue":"6","key":"654_CR40","first-page":"359","volume":"23","author":"J Sheng","year":"2004","unstructured":"Sheng J, Gao Z, Chen M, Zhang M, Liu J. Risperidone vs haloperidol in treatment of behavioral and psychological symptoms of dementia : a randomized, double-blind trial. Chin J New Drugs Clin Rem. 2004;23(6):359\u201362.","journal-title":"Chin J New Drugs Clin Rem."},{"key":"654_CR41","first-page":"156","volume":"37","author":"X Sun","year":"2004","unstructured":"Sun X, Gao Z, Feng F. A randomized double-blind trial of haloperidol and risperidone for behavioral and psychological symptoms of dementia. Chin J Psychiatry. 2004;37:156\u20139.","journal-title":"Chin J Psychiatry."},{"issue":"Suppl. 3","key":"654_CR42","first-page":"363","volume":"8","author":"SR Auer","year":"1996","unstructured":"Auer SR, Monteiro IM, Reisberg B. Behavioral symptoms in dementia: community-based research. Int Psychogeriatr. 1996;8(Suppl. 3):363\u20136.","journal-title":"Int Psychogeriatr."},{"key":"654_CR43","first-page":"546","volume":"6","author":"B Stotsky","year":"1984","unstructured":"Stotsky B. Multicenter study comparing thioridazine with diazepam and placebo in elderly, nonpsychotic patients with emotional and behavioral disorders. Clin Ther. 1984;6:546\u201359.","journal-title":"Clin Ther."},{"key":"654_CR44","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1532-5415.1962.tb00266.x","volume":"10","author":"LD Hamilton","year":"1962","unstructured":"Hamilton LD, Bennett JL. The use of trifluoperazine in geriatric patients with chronic brain syndrome. J Am Geriatr Soc. 1962;10:140\u20137.","journal-title":"J Am Geriatr Soc."},{"key":"654_CR45","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1176\/appi.ajp.159.3.460","volume":"159","author":"BG Pollock","year":"2002","unstructured":"Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. Comparison of citalopram, perphanezine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159:460\u20135.","journal-title":"Am J Psychiatry."},{"key":"654_CR46","volume-title":"ZIP-128-105","author":"Pfizer","year":"1993","unstructured":"Pfizer. ZIP-128-105. New York: Pfizer; 1993."},{"key":"654_CR47","first-page":"534","volume":"31","author":"W Satterlee","year":"1995","unstructured":"Satterlee W, Reams S, Burns PR, et al. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients. Psychopharmacol Bull 1995;31:534.","journal-title":"Psychopharmacol Bull"},{"key":"654_CR48","volume-title":"Ris-bel-14","author":"Janssen Pharmaceutical","year":"1997","unstructured":"Janssen Pharmaceutical. Ris-bel-14. Beerse: Janssen Pharmaceutical; 1997."},{"key":"654_CR49","volume-title":"Ris-int-83 info","author":"Janssen Pharmaceutical","year":"2003","unstructured":"Janssen Pharmaceutical. Ris-int-83. Beerse: Janssen Pharmaceutical; 2003."},{"issue":"2","key":"654_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4088\/JCP.v60n0207","volume":"60","author":"IR Katz","year":"1999","unstructured":"Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60(2):107\u201315.","journal-title":"J Clin Psychiatry."},{"key":"654_CR51","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","volume":"57","author":"J Street","year":"2000","unstructured":"Street J, Clark S, Gannon K, Cummings J, Bymaster F. olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities. Arch Gen Psychiatry. 2000;57:968\u201376.","journal-title":"Arch Gen Psychiatry."},{"key":"654_CR52","unstructured":"Howanitz E, Wisotzek I: Olanzapine versus placebo in the treatment of behavioral disturbances associated with vascular dementia. Poster presented at the 14th Annual Meeting of the American Association for Geriatric Psychiatry, San Francisco; Feb 23\u201326, 2001."},{"issue":"11","key":"654_CR53","first-page":"1065","volume":"63","author":"L Herz","year":"2002","unstructured":"Herz L, Volicer L, Frankenburg F, Colon S, Kittur S. A 6-Week, double-blind comparison of Olanzapine, Risperidone, and Placebo for behavioral disturbance in Alzheimer's disease. J Clin Psychiatry 2002;63(11):1065.","journal-title":"J Clin Psychiatry"},{"key":"654_CR54","volume-title":"A prospective, randomized, double-blind, placebo-controlled, flexible-dose, parallel-group, single-center study to evaluate the safety, tolerability and efficacy of iloperidone compared with placebo in treating psychotic","author":"Novartis Pharma","year":"2002","unstructured":"Novartis Pharma. A prospective, randomized, double-blind, placebo-controlled, flexible-dose, parallel-group, single-center study to evaluate the safety, tolerability and efficacy of iloperidone compared with placebo in treating psychotic. Basel: Novartis Pharma, 2002."},{"key":"654_CR55","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1176\/ajp.120.12.1190","volume":"120","author":"AA Sugerman","year":"1964","unstructured":"Sugerman AA, Williams BH, Adlerstein AM. Haloperidol in the psychiatric disorders of old age. Am J Psychiatry. 1964;120:1190\u20132.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"654_CR56","doi-asserted-by":"publisher","first-page":"134","DOI":"10.4088\/JCP.v64n0205","volume":"64","author":"H Brodaty","year":"2003","unstructured":"Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64(2):134\u201343.","journal-title":"J Clin Psychiatry."},{"key":"654_CR57","first-page":"9","volume-title":"Clinical study report synopsis","author":"Janssen Pharmaceutical","year":"2005","unstructured":"Janssen Pharmaceutical. Clinical study report synopsis. Beerse: Janssen Pharmaceutical; 2005. p. 9\u201312."},{"issue":"2","key":"654_CR58","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/gps.1032","volume":"19","author":"P De Deyn","year":"2004","unstructured":"De Deyn P, Carrasco M, Deberdt W, Jeandel C, Hay D, Feldman P, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2004;19(2):115\u201326.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"7496","key":"654_CR59","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","volume":"330","author":"C Ballard","year":"2005","unstructured":"Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer\u2019s disease: randomised double blind placebo controlled trial. Br Med J. 2005;330(7496):874\u20137.","journal-title":"Br Med J."},{"issue":"8","key":"654_CR60","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1097\/00019442-200508000-00012","volume":"13","author":"WG Deberdt","year":"2005","unstructured":"Deberdt WG, Dysken MW, Rappaport SA, Feldman PD, Young CA, Hay DP, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry. 2005;13(8):722\u201330.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"3","key":"654_CR61","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/01.JGP.0000194643.63245.8c","volume":"14","author":"J Mintzer","year":"2006","unstructured":"Mintzer J, Greenspan A, Caers I, Hove I, Kushner S, Weiner M, et al. Risperidone in the treatment of psychosis of alzheimer disease : results from a prospective clinical trial. Am J Geriatr Psychiatry. 2006;14(3):280\u201391.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"11","key":"654_CR62","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/JGP.0b013e3181557b47","volume":"15","author":"JE Mintzer","year":"2007","unstructured":"Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007;15(11):918\u201331.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"1","key":"654_CR63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/156720507779939805","volume":"4","author":"KX Zhong","year":"2007","unstructured":"Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 2007;4(1):81\u201393.","journal-title":"Curr Alzheimer Res."},{"key":"654_CR64","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/gps.1892","volume":"23","author":"D Paleacu","year":"2008","unstructured":"Paleacu D, Barak Y, Mirecky I, Mazeg D. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer\u2019s disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry. 2008;23:393\u2013400.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"7","key":"654_CR65","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/JGP.0b013e318165db77","volume":"16","author":"JE Streim","year":"2008","unstructured":"Streim JE, Porsteinsson AP, Breder CD, Swanink R, Marcus R, McQuade R, et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry. 2008;16(7):537\u201350.","journal-title":"Am J Geriatr Psychiatry."},{"key":"654_CR66","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1532-5415.1976.tb04280.x","volume":"24","author":"R Rada","year":"1976","unstructured":"Rada R, Kellner R. Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome. J Am Geriatr Soc. 1976;24:105\u20137.","journal-title":"J Am Geriatr Soc."},{"key":"654_CR67","unstructured":"Otsuka Pharmaceutical. 2017a. \n                    http:\/\/www.clinicaltrialsregister.eu\n                    \n                   (EudraCT Number 2013-000504-41)."},{"key":"654_CR68","unstructured":"Otsuka Pharmaceutical. 2017b. \n                    http:\/\/www.clinicaltrailsregister.eu\n                    \n                   (EudraCT Number 2013-000503-17)."},{"issue":"3","key":"654_CR69","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","volume":"17","author":"C Ballard","year":"2018","unstructured":"Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer\u2019s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018;17(3):213\u201322.","journal-title":"Lancet Neurol."},{"key":"654_CR70","unstructured":"ACADIA Pharmaceutical. 2018. \n                    http:\/\/www.clinicaltrials.gov\n                    \n                   (NCT02992132)."},{"issue":"5","key":"654_CR71","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1212\/WNL.53.5.946","volume":"53","author":"PP De Deyn","year":"1999","unstructured":"De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53(5):946\u201355.","journal-title":"Neurology."},{"issue":"4","key":"654_CR72","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s002130050064","volume":"148","author":"H Allain","year":"2000","unstructured":"Allain H, Dautzenberg PH, Maurer K, Schuck S, Bonhomme D, Gerard D, et al. Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology (Berl). 2000;148(4):361\u20136.","journal-title":"Psychopharmacology (Berl)."},{"issue":"9","key":"654_CR73","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/01.JGP.0000196628.12010.35","volume":"14","author":"P Tariot","year":"2006","unstructured":"Tariot P, Schneider L, Katz I, Mintzer J, Street J, Copenhaver M, et al. Quetiapine treatment of psychosis associated with dementia : a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006;14(9):767\u201376.","journal-title":"Am J Geriatr Psychiatry."},{"key":"654_CR74","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1176\/ajp.139.9.1170","volume":"139","author":"R Barnes","year":"1982","unstructured":"Barnes R, Veith R, Okimoto J, Raskind M, Gumbrecht G. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry. 1982;139:1170\u20134.","journal-title":"Am J Psychiatry."},{"key":"654_CR75","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00004714-198204000-00008","volume":"2","author":"W Petrie","year":"1982","unstructured":"Petrie W, Ban T, Berney S, Fujimori M, Guy W, Ragheb M, et al. Loxapine in psychogeriatrics: a placebo- and standard-controlled clinical investigation. J Clin Psychopharmacol. 1982;2:122\u20136.","journal-title":"J Clin Psychopharmacol."},{"issue":"2","key":"654_CR76","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/gps.930100208","volume":"10","author":"SI Finkel","year":"1995","unstructured":"Finkel SI, Lyons JS, Anderson RL, Sherrell K, Davis J, Cohen-Mansfield J, et al. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. Int J Geriatr Psychiatry. 1995;10(2):129\u201336.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"4","key":"654_CR77","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1176\/jnp.9.4.591","volume":"9","author":"AP Auchus","year":"1997","unstructured":"Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer\u2019s disease. J Neuropsychiatry Clin Neurosci. 1997;9(4):591\u20133.","journal-title":"J Neuropsychiatry Clin Neurosci."},{"issue":"11","key":"654_CR78","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1176\/ajp.155.11.1512","volume":"155","author":"DP Devanand","year":"1998","unstructured":"Devanand DP, Marder K, Michaels KS, Sackeim HA, Bell K, Sullivan MA, et al. A radomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer\u2019s disease. Am J Psychiatry. 1998;155(11):1512\u201320.","journal-title":"Am J Psychiatry."},{"issue":"9","key":"654_CR79","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1212\/WNL.55.9.1271","volume":"55","author":"L Teri","year":"2000","unstructured":"Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55(9):1271\u20138.","journal-title":"Neurology."},{"issue":"5","key":"654_CR80","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/01.jcp.0000178415.22309.8f","volume":"25","author":"P De Deyn","year":"2005","unstructured":"De Deyn P, Jeste DV, Swanink R, Kostic D, Breder C, Carson WH, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer\u2019s disease: a randomized, placebo-controlled study. J Clin Psychopharmacol. 2005;25(5):463\u20137.","journal-title":"J Clin Psychopharmacol."},{"key":"654_CR81","first-page":"1","volume":"2","author":"E Lonergan","year":"2010","unstructured":"Lonergan E, Luxenberg J, Colford JM, Birks J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2010;2:1\u201325.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"654_CR82","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jnnp-2014-308112","volume":"86","author":"J Wang","year":"2015","unstructured":"Wang J, Yu J-T, Wang H-F, Meng X-F, Wang C, Tan C-C, et al. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer\u2019s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86(1):101\u20139.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"654_CR83","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3233\/JAD-140579","volume":"42","author":"H Ma","year":"2014","unstructured":"Ma H, Huang Y, Cong Z, Wang Y, Jiang W, Gao S, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42:915\u201337.","journal-title":"J Alzheimers Dis."},{"key":"654_CR84","first-page":"1","volume":"1","author":"C Ballard","year":"2006","unstructured":"Ballard C, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer\u2019s disease (review). Cochrane Database Syst Rev. 2006;1:1\u2013135.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"654_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-015-0102-9","volume":"7","author":"L Tan","year":"2015","unstructured":"Tan L, Tan L, Wang H, Wang J, Tan C, Tan M, et al. Efficacy and safety of atypical antipsychotic drug treatment for dementia : a systematic review and meta-analysis. Alzheimers Res Ther. 2015;7(1):1\u201313.","journal-title":"Alzheimers Res Ther."},{"issue":"3","key":"654_CR86","doi-asserted-by":"publisher","first-page":"e190828","DOI":"10.1001\/jamanetworkopen.2019.0828","volume":"2","author":"I Yunusa","year":"2019","unstructured":"Yunusa I, Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Netw Open. 2019;2(3):e190828.","journal-title":"JAMA Netw Open."},{"issue":"2","key":"654_CR87","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1532-5415.2005.00566.x","volume":"54","author":"S Carson","year":"2006","unstructured":"Carson S, McDonagh MS, Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J Am Geriatr Soc. 2006;54(2):354\u201361.","journal-title":"J Am Geriatr Soc."},{"issue":"7457","key":"654_CR88","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/bmj.38125.465579.55","volume":"329","author":"PE Lee","year":"2004","unstructured":"Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ. 2004;329(7457):75.","journal-title":"BMJ."},{"issue":"15","key":"654_CR89","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"L Schneider","year":"2005","unstructured":"Schneider L, Dagerman K, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. J Am Med Assoc. 2005;294(15):1934\u201343.","journal-title":"J Am Med Assoc."},{"issue":"10","key":"654_CR90","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.jamda.2015.03.015","volume":"16","author":"TA Hulshof","year":"2015","unstructured":"Hulshof TA, Zuidema SU, Ostelo RWJG, Luijendijk HJ. The mortality risk of conventional antipsychotics in elderly patients: a systematic review and meta-analysis of randomized placebo-controlled trials. J Am Med Dir Assoc. 2015;16(10):817\u201324.","journal-title":"J Am Med Dir Assoc."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00654-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-019-00654-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00654-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T23:33:27Z","timestamp":1598744007000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-019-00654-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,31]]},"references-count":90,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["654"],"URL":"https:\/\/doi.org\/10.1007\/s40263-019-00654-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,31]]},"assertion":[{"value":"31 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"EJV contributed to data collection, performed the statistical analysis, and wrote the manuscript. TAH and HJL performed the literature search and contributed to data collection. HJL supervised the study. All authors provided important intellectual content, participated in revising the paper, and approved the final version submitted for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This study was not funded. The open access fee was paid by the Department of General Practice & Elderly Care Medicine, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Eline J. Vredeveld, Tessa A. Hulshof, Hendrika J. Luijendijk, and Sytse U. Zuidema declare they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}